Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · September 12, 2022

Maintenance Therapy With Ponatinib After Allogeneic HSCT in Philadelphia Chromosome–Positive ALL With T315I Mutation

Leukemia Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Leukemia Research
Safety and outcomes of maintenance therapy with third-generation tyrosine kinase inhibitor after allogeneic hematopoietic cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients with T315I mutation
Leuk. Res 2022 Oct 01;121(xx)106930, H Chen, LP Xu, XH Zhang, Y Wang, YH Chen, CH Yan, YF Cheng, W Han, Y Chen, YZ Qin, Y Liu, YJ Chang, KY Liu, XJ Huang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading